Does the HAS-BLED score accurately assess the 1-year risk of major bleeding in patients with atrial fibrillation?
The novel HAS-BLED score provides a practical tool to assess individual 1-year major bleeding risk in real-world patients with atrial fibrillation, supporting clinical decision-making for antithrombotic therapy.
This simple, novel bleeding risk score (HAS-BLED) provides a practical tool to assess the individual bleeding risk of real-world patients with AF, potentially supporting clinical decision making regarding antithrombotic therapy in patients with AF.
Pisters et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: